Table 2.
Haematological and non-haematological side effects*
| Body system | Induction (N = 45) | Maintenance (N = 40) | ||||
|---|---|---|---|---|---|---|
| G1/2, % | G3, % | G4, % | G1/2, % | G3, % | G4, % | |
| Cardiac general | 8.8 | 2.2 | 0 | 2.5 | 0 | 0 |
| Constitutional symptoms | 71.1 | 0 | 0 | 57.5 | 0 | 0 |
| Dermatology/skin | 71.1 | 6.7 | 0 | 42.5 | 2.5 | 0 |
| Gastrointestinal | 62.3 | 2.2 | 0 | 45 | 0 | 0 |
| Hepatobiliary/pancreas | 11.1 | 4.4 | 0 | 2.5 | 2.5 | 0 |
| Infection | 55.6 | 6.7 | 0 | 42.5 | 5 | 0 |
| Lymphatics | 20 | 0 | 0 | 5 | 0 | 0 |
| Neurology | 22.2 | 0 | 0 | 17.5 | 0 | 0 |
| Pain | 53.4 | 2.2 | 0 | 30 | 0 | 0 |
| Pulmonary/upper respiratory (excl. infections) | 8.8 | 0 | 0 | 2.5 | 0 | 0 |
| Renal/genitourinary | 35.5 | 0 | 6.7** | 20 | 0 | 0 |
| Other | 73.3 | 2.2*** | 0 | 50 | 2.5 | 0 |
| Blood/bone marrow (excerpt) | ||||||
| Neutropenia | 26.6 | 35.6 | 35.6 | 17.5 | 45 | 27.5 |
| Thrombocytopenia | 80 | 4.4 | 4.4 | 77.5 | 0 | 2.5 |
| Anaemia | 84.4 | 4.4 | 2.2 | 55 | 0 | 2.5 |
*Percentages refer to number of patients with their maximal CTCAE grading per body system
**Three patients had G4 hyperuricemia without >G2 creatinine increase (no TLS)
***One patient was documented with hypertension/worsening of hearing